Steven Arthur Farber

A zebrafish phenotypic drug screen identifies 49 ApoB-lowering compounds, with enoxolone showing efficacy dependent on HNF4 function, validating the LipoGlo platform for B-lp modulation.

This study shows that loss of asgr1a in zebrafish leads to excess dietary cholesterol excretion rather than hepatic accumulation, suggesting a role for ASGR1 in cholesterol metabolism.

The paper develops a zebrafish reporter to measure atherogenic lipoprotein kinetics and finds that lipolysis is suppressed by high-fat meals.

PeakClimber accurately quantifies complex HPLC chromatograms using exponential Gaussian functions, outperforming existing tools in precision and applicability to biological samples.

WheresWalker is a mutation mapping pipeline that rapidly identifies mutation-containing intervals in whole genome sequencing data, validated in zebrafish and maize.

This paper presents a zebrafish model of Leigh Syndrome, demonstrating liver dysfunction's critical role in mitochondrial disease through genetic rescue.

This study identifies a missense mutation in the furinb gene in zebrafish that causes hepatic cysts by disrupting ER homeostasis and mTOR signaling during liver development.

The paper describes a zebrafish gene break transposon library for genomic discovery and disease modeling, identifying novel gene expression patterns and generating models for human disease loci.

The paper introduces LipoGlo, a system using ApoB-fused luciferase to monitor lipoprotein atherogenicity in zebrafish, revealing new localization patterns and identifying a regulator of lipoprotein size.

The paper analyzes mRNA processing in zebrafish mutant lines to explain why few phenotypes are observed despite predicted gene disruptions.